To elucidate the relationship between oncogenic RAS and HCC progression and the potential utility of the subtyping signatures, we compared prognosis among three clinical subsets, including KRAS, NRAS, and HRAS. This evidence concerns the gene KRAS and hepatocellular carcinoma.